In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Anaplastic Meningioma: A Comprehensive Analysis of Prognostic Factors and Management in 60 Cases from 2003-2008

    Final Number:
    490

    Authors:
    Qing Xie MD, PhD; Hongda Zhu; Ye Gong MD, PhD; Ying Mao MD; Ping Zhong; Fengping Huang MD; Kang Zheng; Yongfei Wang; Weimin Bao; Bojie Yang; Hong Chen; Mingzhe Zheng; Hailiang Tang; Daijun Wang; Xiancheng Chen; Liangfu Zhou

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Anaplastic meningioma is a rare but predominant malignant subtype of meningiomas with a high recurrence rate and poor prognosis, while prognostic factors and optimal management remain controversial.

    Methods: All adult anaplastic meningioma patients treated from 2003 through 2008 at our institution were reviewed in this retrospective study, and the latest follow-up time point was in June 2012. The clinical charts, postoperative treatment, outcomes and treatment after recurrence were analyzed. Kaplan-Meier survival curve and Cox proportional hazards modeling was used to assess possible prognostic factors.

    Results: The mean follow-up period was 48.8 months (1-112 months). Thirty-six patients were at initial presentation and 24 patients had history of previous operated meningiomas. Tumor recurred in 53.3% (32/60) of all patients. Median progression-free survival (PFS) was 42.0 months; 3-and 5-year PFS rates were 56.7% and 26.7%, respectively. Suspected metastases were found in 4 patients. Tumor-induced mortality occurred in 46.7% (28/60) patients with mean interval at 48.8 months after diagnosis (1-72 months). Overall survival rate was 67.7% and 35.5% at 3 years and 5 years, respectively. Of the 32 recurred patients, the median survival time was 14 month. Multivariate analysis identified adjuvant radiotherapy as an independent factor affecting PFS for patients at initial presentation. Among recurred patients, two major factors were associated with a significantly longer OS, one is MIB-1 index less than 5%, and the other is positive treatment after recurrence, such as re-operation and radiotherapy .

    Conclusions: Anaplastic meningioma had a high recurrence rate and possible metastasis, which leads to a high mortality. Combined therapy of surgery and radiotherapy is effective for progression free of patients with first-ever meningioma, and for recurrent patients, reoperation is also recommended if it is feasible. When determining optimal treatment strategies, patients with different initial status and/or MIB-1 index should be considered.

    Patient Care: Since anaplastic meningioma is a devastating disease without established optimal management option, treatment strategies should be explored further in this indication. In this retrospective study, through further subdivision of patients with multimodality therapy and comprehensive analysis, we concluded that combined therapy of surgery and radiotherapy is effective for local control, and for recurrent patients, reoperation is also recommended if it is feasible. More importantly, patients with different initial status and/or MIB-1 index should be discriminated when determining individualized treatment strategies. Further study with a large enough number of patients could lead to more accurate estimates of anaplastic meningioma, and determine the optimal management.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the importance of the combination therapy of operation plus radiotherapy, 2) Discuss, in small groups, further possible study which could lead to more accurate estimates of anaplastic meningioma, and determine the optimal management. 3) Identify an effective treatment for anaplastic meningioma.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy